Adacel + N-acetyl cysteine + alpha lipoic acid + liposomal glutathione

This combination consists of the Adacel vaccine—a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine—administered in conjunction with a nutritional supplement regimen of N-acetyl cysteine (NAC), alpha lipoic acid (ALA), and liposomal glutathione. Adacel, developed by Sanofi Pasteur, is a sterile, adsorbed vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 through 64 years. The supplementary components (NAC, ALA, and glutathione) are included to modulate the systemic redox environment and potentially enhance the host's immune response. NAC serves as a precursor to glutathione, ALA acts as an antioxidant that helps regenerate glutathione, and liposomal glutathione provides a direct source of the tripeptide. This combination is primarily explored in clinical research to determine if improving antioxidant status can boost the immunogenicity and safety profile of the Tdap vaccine, particularly in the context of revaccination studies evaluating long-term immunity (e.g., 10 years post-initial dose).

Brand names

Adacel

Other names

Tdap vaccine + NAC + ALA + GSHAdacel Revaccination Supplement Regimen